The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Vaccines for the 21st Century: A Tool for Decisionmaking
value of the cost per QALY gained is $5,000. If the target population was all 12-year-olds, the annualized present value of the cost per QALY gained is $3,000. Using committee assumptions of less-than-ideal utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the cost per QALY gained is $7,400. If the target population was all 12-year-olds (assuming 50% utilization), the annualized present value of the cost per QALY gained is $4,000.
See Chapters 4 and 5 for details on the methods and assumptions used by the committee for the results reported.
Bhandari BN, Wright TL. Hepatitis C: An Overview. Annual Review of Medicine 1995; 46:309–317.
Lemon SM, Brown EA. Hepatitis C Virus. In: Principles and Practice of Infectious Diseases. GL Mandell, JE Bennett, Dolin R eds. New York, NY: Churchill Livingstone, 1995, pp. 1474–1486.